Loading data for ABT — first visit, this takes a few seconds.

Alerta

Abbott Laboratories (ABT)

NYSE: ABT · Precio en tiempo real · USD

110.37

-0.88 (-0.79%)

Al cierre: Aug 17, 2026, 8:02 PM

111.05

+0.58%

Premercado: 6:32 AM

-0.79% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	190.98B
Ingresos (TTM)	46.58B
Beneficio neto (TTM)	5.4B
Beta	0.58
EPS (TTM)	3.09
Ratio PER (TTM)	35.72
Adelante PE	18.2
P/B (TTM)	3.74
P/S (TTM)	4.13
Earnings Date	Oct 14, 2026

Precio de venta	n/a
Volumen	5,080,839
Volumen medio (20D)	12,056,903
Abierto	110.04
Anterior Cerrar	111.25
Rango del día	109.35 - 111.41
Rango de 52 semanas	81.97 - 137.49
analista	n/a
Precio objetivo	n/a
Dividendos	$2.52 (2.28%)
Fecha ex dividendo	15 jul 2026

Acerca de ABT

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms...

[Leer más]

Industria Medical Devices

Sector Healthcare

IPO Fecha Mar 17, 1980

Empleados 122,000

Bolsa de Valores NYSE

Símbolo bursátil ABT

Sitio web https://www.abbott.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Abbott Laboratories fueron 44.33B, un aumento de 5.67% en comparación con 41.95B del año anterior. Las ganancias fueron 6.52B, una disminución de -51.32%.

Estados financieros

Sorpresa de resultados

Abbott Laboratories ha publicado sus resultados trimestrales en Jul 16, 2026:

Ingresos de n/a falla las estimaciones por $0, con -100.00% Disminución interanual.

EPS de 1.31 supera las estimaciones en 0.03, con 3.97% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Abbott Laboratories publique sus resultados el Oct 14, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 día hace · Simply Wall St.

Abbott (ABT) Stock Looks Reasonable On Earnings With Stronger Cash Flow

Abbott Laboratories stock has delivered a 14.0% total return over the past three years, yet its current checks suggest a mixed valuation picture as the Discounted Cash Flow (DCF) estimate points to me...

1 día hace · Motley Fool

If You Invest $100 a Month in SCHD, Here's the Passive Income It Could Deliver in 20 Years

This top dividend ETF is still a reliable long-term income investment.

1 día hace · Simply Wall St.

What Does Abbott Laboratories (ABT) Gain From This New App Controlled Pump Rollout?

Abbott Laboratories (NYSE:ABT) is supplying its Instinct sensor for MiniMed's newly shipped app-controlled insulin pump in the U.S. The system pairs what MiniMed describes as the world's smallest app-...

1 día hace · Zacks

QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns

QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.

1 día hace · Zacks

Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

Página 1 de 2

Abbott Laboratories (ABT)